Juvenescence is a biopharmaceutical company that has raised USD $168 million since 2017 to build a pipeline of therapeutic assets to target aging, regeneration and the diseases of aging.
As people age, complex changes occur at the genomic, cellular and tissue level, from the accumulation of DNA damage to mitochondrial dysfunction and altered intercellular communication.
These changes, among others, cause the diseases of aging that affect the elderly, and the chronic illnesses that are the biggest burden on the healthcare system.
Aging is the largest health problem facing the world today; two-thirds of all deaths worldwide are as a result of the aging process, with many years of degeneration reducing quality of life before death.
Our work is based on novel scientific understanding of the underlying biological causes of aging, to create evidence-based therapeutics that can treat diseases of aging.
Juvenescence creates and partners with new companies with longevity-related therapeutics, by in-licensing compounds from academia and industry, or forming joint ventures with the foremost longevity scientists and leading research institutions.
Juvenescence aims to create a paradigm shift in addressing and treating disease.
Our goal is to extend both lifespan and healthspan, by developing therapeutics that slow aging and promote juvenescence (”the state or period of being young”).
Ultimately, Juvenescence aims to get therapeutics to patients, and eradicate life-shattering diseases that cause people to suffer until death.
Juvenescence leverages its world-class team to translate rigorous science into disease-modifying therapeutics.
Our growing pipeline of therapeutic assets targets fundamental aging, regeneration, and the diseases of aging. Click below to the full pipeline to learn more about each company.
Greg Bailey interview with ‘The Simple BioTech Podcast’
Greg Bailey, the CEO of Juvenescence, discusses Juvenescence and some of the innovations within the longevity space. Interview with ‘The Simple BioTech Podcast’. ‘The Simple BioTech Podcast’ found here.Read more
Juvenescence Appointment of CEO for Souvien & Epigenetic Division
Juvenescence Limited, a life sciences company focused on modifying aging and increasing human healthspan, is pleased to announce the appointment of Dr. Ellen Donnelly to its Senior Leadership Team. Ellen joins the Juvenescence team as the CEO of the Epigenetics Division of Juvenescence and CEO of our portfolio company, Souvien…Read more
Please complete the form below to get in touch with the Juvenescence team.